Lintuzumab (SGN-33, HuM195) is an unconjugated anti-CD33 mAb which has been tested in several clinical trials for AML (NCT00002609, NCT00002800, NCT00006084, NCT00016159, NCT00283114, NCT00502112, NCT00528333, and NCT00997243) in combination with standard induction chemotherapy and a maintenance monotherapy in R/R AML (reviewed in [100]). This evidence concerns the gene CD33 and acute myeloid leukemia.